COMP <GO>
ALMR vs CTKB // RETURN ON INVESTED CAPITAL (ROIC)
Alamar Biosciences Inc. (NASDAQ) VS. Cytek Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: ALMR 1
— CTKB 1
■ METRIC PARITY
LAST: $30.60 (-10.11%) • MKT CAP: $2.36B
roic
—
LAST: $6.13 (-2.70%) • MKT CAP: $818.9M
roic
-12.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALMR VS. CTKB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALMR | CTKB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 51.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | — | -12.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -1.07% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -20.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -33.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 0.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.76 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.5 | 68.7 | -11.20 | CTKB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.36B | $818.9M | $1.54B | ALMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALMR REV | CTKB REV | ALMR GROSS % | CTKB GROSS % | ALMR FCF | CTKB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $201.5M | — | 51.8% | — | -$8.8M |
| FY 2024 | — | $200.5M | — | 55.4% | — | $21.9M |
| FY 2023 | — | $193.0M | — | — | — | $5.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALMR // BETA —
CTKB // BETA —